AbCellera and Bruker reached a settlement resolving longstanding patent litigation tied to single‑cell antibody discovery and microfluidic technologies. Under the agreement Bruker will pay AbCellera $36 million and ongoing royalties on sales of Bruker’s Beacon Optofluidic platform that use the licensed patents. The dispute traces back to earlier claims involving Berkeley Lights and subsequent asset transfers; the settlement removes a commercial overhang and clarifies licensing for microfluidics and single‑cell discovery tools.